X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Aventis Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA SANOFI INDIA SHASUN PHARMA/
SANOFI INDIA
 
P/E (TTM) x 123.9 33.6 369.3% View Chart
P/BV x 8.5 6.4 133.5% View Chart
Dividend Yield % 0.2 1.4 16.5%  

Financials

 SHASUN PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
SANOFI INDIA
Dec-16
SHASUN PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs944,560 2.1%   
Low Rs464,400 1.0%   
Sales per share (Unadj.) Rs214.21,028.5 20.8%  
Earnings per share (Unadj.) Rs5.3129.0 4.1%  
Cash flow per share (Unadj.) Rs15.8186.0 8.5%  
Dividends per share (Unadj.) Rs1.0068.00 1.5%  
Dividend yield (eoy) %1.41.5 94.3%  
Book value per share (Unadj.) Rs53.3753.6 7.1%  
Shares outstanding (eoy) m56.6223.03 245.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.34.4 7.5%   
Avg P/E ratio x13.134.7 37.7%  
P/CF ratio (eoy) x4.424.1 18.3%  
Price / Book Value ratio x1.35.9 22.0%  
Dividend payout %18.752.7 35.5%   
Avg Mkt Cap Rs m3,958103,174 3.8%   
No. of employees `000NA3.6 0.0%   
Total wages/salary Rs m2,1643,592 60.2%   
Avg. sales/employee Rs ThNM6,537.7-  
Avg. wages/employee Rs ThNM991.4-  
Avg. net profit/employee Rs ThNM819.8-  
INCOME DATA
Net Sales Rs m12,12723,686 51.2%  
Other income Rs m229708 32.4%   
Total revenues Rs m12,35624,394 50.7%   
Gross profit Rs m1,0095,281 19.1%  
Depreciation Rs m5941,313 45.2%   
Interest Rs m41515 2,767.3%   
Profit before tax Rs m2304,661 4.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-731,691 -4.3%   
Profit after tax Rs m3022,970 10.2%  
Gross profit margin %8.322.3 37.3%  
Effective tax rate %-31.736.3 -87.3%   
Net profit margin %2.512.5 19.9%  
BALANCE SHEET DATA
Current assets Rs m6,88415,673 43.9%   
Current liabilities Rs m8,4566,678 126.6%   
Net working cap to sales %-13.038.0 -34.1%  
Current ratio x0.82.3 34.7%  
Inventory Days Days6276 81.1%  
Debtors Days Days10822 482.0%  
Net fixed assets Rs m4,9708,098 61.4%   
Share capital Rs m113230 49.2%   
"Free" reserves Rs m2,87517,088 16.8%   
Net worth Rs m3,02017,356 17.4%   
Long term debt Rs m1,8170-   
Total assets Rs m13,34725,400 52.5%  
Interest coverage x1.6311.7 0.5%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.90.9 97.4%   
Return on assets %5.411.8 45.7%  
Return on equity %10.017.1 58.5%  
Return on capital %13.326.9 49.5%  
Exports to sales %46.424.5 189.3%   
Imports to sales %14.228.0 50.9%   
Exports (fob) Rs m5,6225,801 96.9%   
Imports (cif) Rs m1,7286,627 26.1%   
Fx inflow Rs m5,8437,145 81.8%   
Fx outflow Rs m2,1736,846 31.7%   
Net fx Rs m3,669299 1,227.3%   
CASH FLOW
From Operations Rs m3983,226 12.3%  
From Investments Rs m-1,635-1,555 105.1%  
From Financial Activity Rs m1,309-1,818 -72.0%  
Net Cashflow Rs m71-147 -48.4%  

Share Holding

Indian Promoters % 39.2 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 3.6 14.4 25.0%  
FIIs % 17.6 14.6 120.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 10.5 377.1%  
Shareholders   20,750 15,184 136.7%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   VENUS REMEDIES  MERCK LTD  GSK PHARMA  J.B.CHEMICALS  ORCHID PHARMA LTD  

Compare SHASUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 8-QTR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS